Tag: CAR T-cell

The first phase 3 results from the CARTITUDE-4 trial of ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in lenalidomide-refractory multiple myeloma (MM) demonstrated the former’s convincing superiority in several key outcomes. Presented during the plenary session at the European Hematology Association 2023 Congress by Hermann Einsele, MD, FRCP of…

NEW YORK – The US Food and Drug Administration granted Kyverna Therapeutics fast–track designation for KYV-101, the cell therapy developer said last week. KYV-101 is an autologous therapy designed to treat refractory lupus nephritis, a serious complication of lupus. The treatment is a CAR T–cell therapy that aims to deplete a…

CNS Relapse Incidence and Survival Outcomes in Patients With High-Risk DLBCL Receiving High-Dose Methotrexate CNS Prophylaxis | PracticeUpdate …

Tycel Phillips, MD, associate professor, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma and the potential impacts the drug’s recent approval will have in the community oncology setting. Transcript Can you describe…

Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, appears to have curative potential for a subset of patients with refractory large B-cell lymphoma (LBCL), according to research published in Blood. On the basis of data from ZUMA-1 (ClinicalTrials.gov Identifier: NCT02348216), an open-label phase 1/2 study of…

Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines of therapy and failed to respond to standard Revlimid (lenalidomide). That’s according to the first data analysis, at nearly 1.5 years of follow-up, of the ongoing…

Although rare, patients should be monitored for thrombotic events while receiving chimeric antigen receptor (CAR) T-cell therapy, explain researchers of a new study published in International Journal of Molecular Sciences. The study, wrote the researchers, offers insight into emerging and uncommon complications following CAR T-cell therapy. To date, little has…

Approval of the first-in-class, subcutaneously administered T-cell–engaging bispecific antibody epcoritamab-bysp (Epkinly) provides an effective alternative to chemotherapy for patients with diffuse large B cell lymphoma (DLBCL) in the third-line setting, according to Tycel Phillips, MD. On May 19, 2023, single-agent epcoritamab gained FDA approval for the treatment of patients with…

Image Credit: © LASZLO – www.stock.adobe.com A retrospective analysis of patients receiving chimeric antigen receptor (CAR) T-cell therapy identified risk factors and potential indicators for serious coagulopathy related to therapy, according to published findings from the phase 1 LEGEND-2 study (NCT03090659).1 Of 51 patients treated in LEDEND-2, 49% developed coagulation…

The CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) outperformed high-dose chemotherapy and autologous stem cell transplantation (ASCT) in a cohort of patients aged 65 years or older with relapsed/refractory large B-cell lymphoma (LBCL), according to findings from a subgroup analysis of the phase 3 ZUMA-7 trial (NCT03391466). “Taken together,…

Editor’s note: This is an automatically generated transcript. Please notify hliptak@healio.com if there are concerns regarding accuracy of the transcription. Diffuse large B-cell lymphoma is the most common form of lymphoma, but despite very good frontline treatment, about a third of patients will have relapsed or refractory disease, meaning they…

Editor’s note: This is an automatically generated transcript. Please notify hliptak@healio.com if there are concerns regarding accuracy of the transcription. One is the cases of the patients who have, you know, are relatively young and fit, maybe in their fifties or sixties, and have really difficult-to-control lymphoma. In that case,…

Gene editing, once a concept of science fiction alone, is now on the cusp of real-life implementation for the first time and 2023 will likely see the global approval of the first CRISPR-based therapy, exa-cel. Vertex, who produce the therapy, has regulatory submissions underway in the USA and EU for…

Salles asks the committee how the treatment of patients with DLBCL varies in different countries, including the categorization of patients into various groups and what key factors are taken into consideration. The committee focus on the current use of clinical pathology for the diagnosis of subtypes and how this has…

Skeletal muscle measurements may be relevant for risk stratification prior to chimeric antigen receptor (CAR) T-cell therapy, including the risk of a patient developing immune effector cell-associated neurotoxicity syndrome (ICANS) and disease response, according to findings from a retrospective cohort study.1 “CAR T has changed the landscape for relapsed DLCL….

Transcript: Andre H. Goy, MD: I want to go back to wrap up this conversation. In the second-line setting, now that we have multiple drugs approved, when you see a patient—I know we touched on this a little as we discussed every topic—summarize for our audience how to decide what…

Transcript: Andre H. Goy, MD: We cure a very large fraction of patients with large cell lymphoma, and CAR [chimeric antigen receptor] T-cell therapy now cures a fraction of the patients. In large cell lymphoma, we probably cure close to 40% with anti-CD19 CAR T-cell therapy. So as you mentioned,…

Chimeric antigen receptor (CAR) T-cell therapy was well tolerated by patients with relapsed/refractory large B-cell lymphoma (LBCL) who were not eligible for autologous transplant due to older age or comorbidities. Efficacy outcomes, including response and survival, were similar among patients not eligible for transplant compared with eligible patients. The results…

urbazon/E+ via Getty Images Life is what happens to us while we are making other plans.” – Allen Saunders. Today, we revisit Fate Therapeutics, Inc. (NASDAQ:FATE). This is a name I have not taken an in-depth look at in years but comes up from time to time on Live Chat….

FDA Approves Epkinly (epcoritamab-bysp) Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) NORTH CHICAGO, Ill., May 19, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp), as the first and only T-cell…

Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of response in challenging-to-treat R/R DLBCL patients EPKINLY represents the seventh approved medicine incorporating Genmab (NASDAQ:) innovation and third created via Genmab’s DuoBody® technology platform…

The FDA has approved the first T-cell–engaging bispecific antibody, epcoritamab-bysp (Epkinly), for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBCL), after 2 or more lines of systemic therapies.1,2 It is recommended…

The FDA granted approval to epcoritamab-bysp (Epkinly) as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, as well as DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma following 2 or more prior lines of therapy, according to a press release from the FDA.1…

The FDA has approved epcoritamab-bysp (Epkinly; AbbVie) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma (HGBL) after 2 or more lines…

The FDA granted accelerated approval to epcoritamab (Epkinly) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B‑cell lymphoma on Friday. The approval allows the drug’s use after two or more lines of systemic therapy in patients with relapsed or refractory DLBCL, not…

GILEAD  AND  KITE  ONCOLOGY  TO  SHOWCASE  ADVANCES  ACROSS  THE  PIPELINE  AIMING  TO  ADDRESS  UNMET  NEEDS  IN  CANCER  CARE  AT  ASCO  2023 – Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Haematologic, Genitourinary, Gastrointestinal, Gynaecological and Other Solid Tumours –   –…

In this issue of Blood, Roddie et al report results from the phase 1 ALEXANDER trial using a novel bicistronic anti-CD19 and anti-CD22 dual-targeted autologous chimeric antigen receptor (CAR) T-cell product, AUTO3, in combination with pembrolizumab, as a third-line or later treatment in patients with relapsed/refractory large B-cell lymphomas (LBCLs).1 Currently…

Transcript: Andre H. Goy, MD: Back to the CAR [chimeric antigen receptor] T cells. We talked a little bit about this, but where does CAR T-cell therapy currently fit in your paradigm, given the fact that we have the second line and third line? If you can just give a…

Diffuse large B-cell lymphoma (DLBCL) made headlines earlier this year with the high-profile case of prominent U.S. Congressman Jamie Raskin (D-MD). Yet, until very recently, progress in treating this most common form of lymphoma has been stalled for more than 2 decades. Significant breakthroughs have come in just the past…

The FDA has granted fast track designation to the CD19/CD20 CAR T-cell therapy IMPT-314 for patients with relapsed/refractory aggressive B-cell lymphoma, according to a press release from ImmPACT Bio USA, Inc. In an investigator-led phase 1 study conducted at UCLA, IMPT-314 produced no instances of cytokine release syndrome greater than…

Stephen J. Schuster, MD Director, Lymphoma Program Director, Lymphoma Translational Research Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research Penn Medicine Philadelphia, PA Targeted Oncology: What led to the use of the tafasitamab (Monjuvi) plus lenalidomide (Revlimid) regimen in patients with relapsed/refractory diffuse…

The FDA has granted fast track designation to IMPT-314, a potential first-in-class CD19/CD20 chimeric antigen receptor (CAR) T therapy for the treatment of patients with B-cell mediated malignancies, according to ImmPACT Bio.1 The potential indications for OMPT-314include for patients with relapsed or refractory (R/R) aggressive B-cell lymphoma, diffuse large B-cell…

Image Credit: © David A Litman – stock.adobe.com Maintenance therapy with a PD-1 inhibitor appear to be an effective and safe treatment for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who achieved a complete response (CR) and a partial response (PR) with previous anti-CD19-CAR T-cell therapy.1 Patients with…

Transcript: Andre H. Goy, MD: Generally speaking, how has the treatment paradigm of large cell lymphoma shifted in recent years? In particular, how many patients develop relapsed/refractory disease? Andrew Ip, MD: It’s probably easier to answer the second question. There are already great statistics from the post-rituximab era from the…

NEW YORK – Researchers at the University of Miami’s Sylvester Comprehensive Cancer Center are launching a research project that will use whole-genome sequencing as well as single-cell transcriptomics to study tumor resistance to cell therapies. Last month, the team announced a three-year, $1.5 million grant from the US Department of…

© Shutterstock Horsham-based Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, recently entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group (CBMG) to develop, manufacture and commercialize chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. B-cell malignancies are…

Yazan Samhouri, MD, a hematologist/oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network (AHN), discusses some of the current research that his team at AHN is working on. According to Samhouri, experts at AHN have been advancing treatments for patients, including taking a giant leap forward…

PRESS RELEASE Published May 5, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in the Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor…

Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneously Publication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR T-cell approach MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”),…

Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into a worldwide collaboration and licensing agreement with Cellular Biomedicine Group (CBMG) for a pair of CAR T-cell therapy candidates. Under the terms of the agreement, Janssen will pay CBMG an upfront fee of $245m, with…

Transcript: Andrew Ip, MD: Now that we have all these updates, exciting research, and further studies to probably do, what are you doing now in a patient in front of you in the second-line setting, especially with relapsed mantle cell lymphoma? What are you telling them is their best option…

CD19-directed CAR T-cell therapy Breyanzi has been approved by the European Commission (EC) based on significant results from a lymphoma Phase III trial. The European Commission (EC) has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The CAR T-cell therapy has a 4-1BB…

COVINA, Calif., May 3, 2023 /PRNewswire/ — According to Prophecy Market Insights “Cell and Gene Therapy Market accounted for US$ 13.0 billion in 2022 and is estimated to be US$ 62.5 billion by 2032 and is anticipated to register a CAGR of 22.8%.” What is the Overview of Cell and Gene Therapy…

When treatment for diffuse large B-cell lymphoma (DLBCL) successfully kills all detectable lymphoma cells, it’s considered a complete response (CR). If you don’t experience a CR or your lymphoma comes back, you may need to try other types of treatments. Experiencing a complete response means you’re more likely to have…

In patients with diffuse large B-cell lymphoma (DLBCL), early lymphopheresis for chimeric antigen receptor (CAR) T-cell therapy, ie, at first relapse before salvage treatment, leads to improved T-cell composition and functionality, a new study published in the British Journal of Haematology found. The improved phenotype and function of T cells…

DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016). Article  PubMed  Google Scholar  Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to…

–  24 leading bone marrow transplant (BMT) centers that perform over 30% of transplants in the U.S. participated in the SIERRA trial that enrolled patients with active relapsed or refractory acute myeloid leukemia –  Demonstration of rapid ability and ease of adoption for Iomab-B infusions at SIERRA sites NEW YORK,…

Kite’s two CAR T-Cell therapies involve treating several different types of blood cancer Kite – a Gilead Sciences spin out company – has announced that the National Institute for Health and Care Excellence (NICE) has recommended additional uses for their two CAR T-cell therapies. The treatments represent…

Kite – a Gilead company – has announced that two of its CAR T-cell therapies have been recommended by the National Institute for Health and Care Excellence (NICE) as options to treat certain aggressive blood cancers. The treatments, both given as one-off infusions, have been specifically recommended for use within…

– EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. – Iomab-B enabled unprecedented 100% bone marrow transplant access and engraftment with 75% post-BMT CR rate in patients with active, relapsed or…

–  EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. –  Iomab-B enabled unprecedented 100% bone marrow transplant access and engraftment with 75% post-BMT CR rate in patients with active, relapsed or…

*Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma *The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily…

Roche administration and research and development centre. Credit: F. Hoffmann-La Roche Ltd. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Roche’s Columvi (glofitamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients after…

In a first, more adult patients living with certain forms of blood cancer will now be able to access CAR T-cell therapy on the UK’s National Health Service (NHS).   US biotech major Gilead Sciences (Nasdaq: GILD) and its Kite subsidiary announced that the National Institute for Health and Care Excellence (NICE) has recommended additional uses…

Most patients with diffuse large B-cell lymphoma (DLBCL) will be cured with up-front chemoimmunotherapy, but 30%-40% of patients will experience relapsed disease. Historically, salvage chemotherapy followed by autologous stem-cell transplant (ASCT) was the mainstay of treatment for these patients. However, research has demonstrated that patients with primary refractory or early…

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily…

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of glofitamab (Columvi) for fixed-duration use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following 2 or more lines of systemic therapy.1 The recommendation is supported by findings from a…

In newly published analysis, Kite’s CAR T-cell therapy delivered a reduced median European manufacturing turnaround time for diffuse large B-cell lymphoma (DLBCL) patients. Yescarta® (axicabtagene ciloleucel or axi-cel) has achieved a median European commercial manufacturing turnaround time of 19 days for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)….

Cyrus Khan, MD Hematologist Allegheny Health Network Cancer Institute Pittsburgh, PA CASE SUMMARY A 43-year-old woman presented with fatigue and worsening, burning back pain. She had a medical history of mild hypertension that was well controlled with medication and her physical exam showed a 1.5-cm left posterior cervical node, a…

Bookmark (0) Please login to bookmark No account yet? Register Is Stem Cell Transplantation Still a Treatment Option for Some DLBCL Patients? from Patient Empowerment Network on Vimeo. Can diffuse large B-cell lymphoma (DLBCL) patients expect to undergo stem cell transplant? Expert Dr. Nirav Shah from the Medical College of…

A bispecific chimeric antigen receptor (CAR) T-cell therapy has shown “robust” activity in patients with relapsed/refractory non-Hodgkin lymphoma, according to a presentation at the AACR Annual Meeting 2023. The CD19/CD20-directed CAR T-cell therapy produced a 91% overall response rate and a 73% complete response rate in this phase 1 trial. …

The FDA has granted approval to polatuzumab vedotin-piiq (Polivy) in combination with rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) as a treatment for patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to a press release from Genentech.1 “This approach with [polatuzumab plus R-CHP] is a first-line therapy that…

Christopher R. Flowers, MD, MS, FASCO, spoke with CancerNetwork® prior to the approval of polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) about how the regimen would benefit patients with previously untreated diffuse large B-cell lymphoma (DLBCL).1 Flowers, a professor and chair in the Department of Lymphoma/Myeloma…

Stops and Starts Abound in the Oncology Payment Landscape The landscape of policies and processes surrounding cancer treatment and financial aspects of care is evolving, with each new rule affecting oncologists and patients. In a presentation March 10 at the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business…

The FDA has accepted a supplemental biologics license application (sBLA) seeking the approval of idecabtagene vicleucel (ide-cel; Abecma) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.1 The FDA has assigned…

Transcript Announcer:Welcome to CME on ReachMD. This episode is part of our MinuteCME curriculum. Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.   Dr. Rutherford:Hello. This is CME on ReachMD, and I’m Dr. Sarah Rutherford from…

PRESS RELEASE Published April 17, 2023 DelveInsight’s, “CAR-T Pipeline Insights 2023” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route…

Gilles Salles, MD Chief of Lymphoma Service Steven A. Greenberg Chair Memorial Sloan Kettering Cancer Center New York, NY Targeted OncologyTM: What are your thoughts on the dosing schedule of the phase 2 L-MIND trial (NCT02399085) of tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid)? SALLES: During cycles 1 to 3, [patients on…

Currently approved chimeric antigen receptor (CAR) T cells are designed to recognize and bind to a single cell surface tumor target. While this has been effective treatment approach, malignant cells can develop resistance by concealing the target antigen; hindering treatment efficacy and leading to cancer recurrence and disease progression.1 Dual-targeted…

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), but barriers to referral for CAR T-cell therapy may obstruct patient access to it, according to a review published in Transplantation and Cellular Therapy. Patients who are refractory to…

April 13, 2023 3 min read Source/Disclosures Published by: Source: Gao W, et al. Abstract HSR23-118. Presented at: NCCN Annual Conference; March 31-April 2, 2023; Orlando. Disclosures: AbbVie and Genmab sponsored this study. Lahue reports employment with Alkemi and an advisory board role with EvoEndo. Please see…

PRESS RELEASE Published April 11, 2023 United States, NY, 11230, Brooklyn Reports and Insights freshly added a report titled “Central Labs Market: Opportunity Analysis and Future Assessment 2023-2031” in its database of market research reports which offers its readers a detailed and profound analysis on the fresh growth opportunities, trends…

Ann F. Mohrbacher, MD Associate Professor of Clinical Medicine Medical Director, Autologous Bone Marrow Transplant Keck School of Medicine of USC Los Angeles, CA Targeted OncologyTM: What are the recommended second-line therapy regimens for patients with relapsed or refractory DLBCL who will proceed to transplant? MOHRBACHER: Based on the NCCN…

Ariel Perez, MD, a hematologist and medical oncologist at Miami Cancer Institute of Baptist Health South Florida, discusses polatuzumab vedotin (Polivy) in combination with bendamustine (Bendeka) and rituximab (Rituxan; Pola-BR) since garnering approval from the FDA and studies that evaluated the combination. Treatment with Pola-BR in patients with relapsed/refractory large…

AsianScientist (Mar. 30, 2023) — Lymphoma is a type of blood cancer that develops in the lymphatic system, an essential part of the immune system that regulates bodily fluids and immune responses. Typically affecting the lymphocytes, a form of white blood cell, this complex disease has numerous subtypes that are…

Chimeric antigen receptor (CAR) T-cell therapies have demonstrated significant efficacy in patients with relapsed/refractory B-cell malignancies following multiple lines of therapy, with various CAR T cell products now U.S. Food and Drug Administration (FDA) approved for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), mantle-cell…

NEW YORK ­­­­­­­­­­­­– Transposable element (TE) promoters that get reactivated in cancer cells can lead to chimeric transcripts involving parts of protein-coding genes, resulting in cancer-specific cell surface antigens, a new study has found. The findings point to potential new treatment strategies, including immunotherapy and a pan-cancer vaccine. TEs, also…

PRESS RELEASE Published March 27, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor T-Cell…

PRESS RELEASE Published March 24, 2023 Reports and Insights freshly added a report titled “Central Labs Market: Opportunity Analysis and Future Assessment 2023-2031” in its database of market research reports which offers its readers a detailed and profound analysis on the fresh growth opportunities, trends and growth drivers that are…

Sehn, L. H., & Salles, G. (2021). Diffuse Large B-Cell Lymphoma. The New England journal of medicine, 384(9), 842–858. Chow, V. A., Shadman, M., & Gopal, A. K. (2018). Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood, 132(8), 777–781. Sadelain, M., Brentjens, R.,…

Bruce D. Cheson, MD (Moderator) Hematologist/Oncologist The Center for Cancer and Blood Disorders Bethesda, MD CASE SUMMARY A 68-year-old man presented with fatigue, back pain, and lymphadenopathy. He had a prior history of medically controlled hypertension. A physical exam showed a 1.5-cm left posterior cervical node, a 2.5-cm right anterior…

Gilles Salles, MD Chief of Lymphoma Service Steven A. Greenberg Chair Memorial Sloan Kettering Cancer Center New York, NY Targeted OncologyTM: How do the National Comprehensive Cancer Network (NCCN) guidelines recommend treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) based on the outcomes of first-line therapy? SALLES: [Looking at]…

NEW YORK – The White House Office of Science and Technology Policy on Wednesday laid out priorities to advance biotechnology and biomanufacturing in the US over the next 20 years, including goals for health monitoring, multiomics, cell therapies, artificial intelligence-driven drug development, gene editing, microbial genome sequencing, and synthetic biology….

Gene therapy has been headline news in recent years, in part due to the rapid development of biotechnology that enables doctors to administer such treatments. Broadly, gene therapies are techniques used to treat or prevent disease by tweaking the content or expression of cells’ DNA, often by replacing faulty genes…

For patients with hematologic malignancies who experience CAR T-cell therapy–induced cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), siltuximab (Sylvant) may be an effective treatment option, according to data presented at the 2023 Transplantation and Cellular Therapy Meetings. The results come from an interim analysis of an…

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, representing 40% of the total cases reported. This cancer originates from the germinal center and represents a widely heterogenous group of diseases.  DLBCL used to include primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, Epstein-Barr virus associated with positive…

PRESS RELEASE Published March 15, 2023 DelveInsight’s, “CAR-T Pipeline Insights 2023,” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including CAR-T clinical trial and nonclinical stage products. It also covers the CAR-T pipeline therapeutics assessment…

CE Activity Release Date: March 15, 2023CE Activity Expiration Date: February 28, 2024 Time to Complete activity: 1 hour ACTIVITY DESCRIPTION Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been…

Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological therapy in 1891. Soon enough, the transformative power of cancer vaccines were observed where tumor-specific antigens triggered antitumor immune responses….

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has significantly improved therapeutic management in patients with relapsed/refractory (R/R) aggressive B-cell lymphomas, demonstrated by its efficacious responses in the JULIET, ZUMA-1, TRANSFORM trials, and real-world studies such as CIMBTR, CART consortium registry, and French, Spanish and German multi-centric studies. Despite these promising…

Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses findings from a preplanned interim futility analysis of the single-arm phase 2 DALY II USA trial (NCT04792489) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The DALY II USA trial is investigating the efficacy and safety of freshly administered…

Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented…

The treatment landscape for patients with lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), has undergone significant changes with the advent of chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies. However, challenges and questions remain in this space. According toMatthew Matasar, MD, one of the major highlights…

Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer. The clinical trial to be conducted by Peter Mac will be the first time…

Ozgu Arslan/iStock via Getty Images In an earlier piece, I discussed the investment potential of CRISPR Therapeutics AG (NASDAQ:CRSP), a gene-editing startup that utilizes the CRISPR/Cas9 technology to develop therapies. The technology enables the elimination or substitution of faulty genes, creating the possibility of a cure for incurable diseases. CRISPR’s…

Background Lymphoma is a group of heterogeneous hematological malignancies, which are classified into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL. DLBCL can be divided into germinal center B-cell-like (GCB) subgroup and non-GCB subgroup according to the origin of cells….

Knowing a patient’s baseline performance are critical to effectively recognize and respond to toxicities with CAR-T cell therapy, according to Jacqueline T. Norrell, FNP-BC. Norrell, who is an advanced practice nurse and the director of nursing clinical informatics at Rutgers Cancer Institute, recently sat down with Oncology Nursing News® to…

A phase II study of glofitamab showed the bispecific monoclonal antibody produced durable complete responses (CR) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).1 A supplemental analysis showed that even patients who received doses lower than the phase II dosage had lasting responses once they had…

Zamtocabtagene autoleucel produced “promising responses” in a phase 2 trial of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a presentation at the Tandem Meetings 2023. Zamtocabtagene autoleucel is a chimeric antigen receptor (CAR) T-cell therapy targeting both CD19 and CD20. Fresh, not cryopreserved, zamtocabtagene autoleucel produced an…

A number of new studies in lung cancer have started in recent months. Could one of your patients benefit from participating? Untreated advanced non–small cell lung cancer (NSCLC). Adult patients with stage IIIB, IIIC, or IV disease without actionable genomic alterations can join a randomized, open-label, phase 3 study testing…